Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage.

Galectin-3 (Gal-3) is increased in heart failure (HF) and promotes cardiac fibrosis and inflammation. We investigated whether Gal-3 modulates oxidative stress in human cardiac fibroblasts, in experimental animal models and in human aortic stenosis (AS). Using proteomics and immunodetection approaches, we have identified that Gal-3 down-regulated the antioxidant peroxiredoxin-4 (Prx-4) in cardiac fibroblasts. In parallel, Gal-3 increased peroxide, nitrotyrosine, malondialdehyde, and N-carboxymethyl-lysine levels and decreased total antioxidant capacity. Gal-3 decreased prohibitin-2 expression without modifying other mitochondrial proteins. Prx-4 silencing increased oxidative stress markers. In Gal-3-silenced cells and in heart from Gal-3 knockout mice, Prx-4 was increased and oxidative stress markers were decreased. Pharmacological inhibition of Gal-3 with modified citrus pectin restored cardiac Prx-4 as well as prohibitin-2 levels and improved oxidative status in spontaneously hypertensive rats. In serum from 87 patients with AS, Gal-3 negatively correlated with total antioxidant capacity and positively correlated with peroxide. In myocardial biopsies from 26 AS patients, Gal-3 up-regulation paralleled a decrease in Prx-4 and in prohibitin-2. Cardiac Gal-3 inversely correlated with Prx-4 levels in myocardial biopsies. These data suggest that Gal-3 decreased Prx-4 antioxidant system in cardiac fibroblasts, increasing oxidative stress. In pathological models presenting enhanced cardiac Gal-3, the decrease in Prx-4 expression paralleled increased oxidative stress. Gal-3 blockade restored Prx-4 expression and improved oxidative stress status. In AS, circulating levels of Gal-3 could reflect oxidative stress. The alteration of the balance between antioxidant systems and reactive oxygen species production could be a new pathogenic mechanism by which Gal-3 induces cardiac damage in HF.

[1]  P. Rossignol,et al.  Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats , 2018, Journal of hypertension.

[2]  J. Egido,et al.  Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development. , 2017, Clinical science.

[3]  F. Jaisser,et al.  Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts , 2017, Scientific Reports.

[4]  F. Jaisser,et al.  Differential proteomics reveals S100-A11 as a key factor in aldosterone-induced collagen expression in human cardiac fibroblasts. , 2017, Journal of proteomics.

[5]  P. Rossignol,et al.  Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model , 2017, International journal of molecular sciences.

[6]  G. Thompson,et al.  The association between oxidative stress‐induced galectins and differentiation of human promyelocytic HL‐60 cells , 2017, Experimental cell research.

[7]  P. Rossignol,et al.  A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. , 2017, Clinical science.

[8]  Hui Luo,et al.  Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. , 2017, Journal of the American Society of Hypertension : JASH.

[9]  J. Joven,et al.  Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation , 2017, International journal of molecular sciences.

[10]  P. Rossignol,et al.  Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage , 2016, PloS one.

[11]  P. Rossignol,et al.  Role for Galectin‐3 in Calcific Aortic Valve Stenosis , 2016, Journal of the American Heart Association.

[12]  R. D. de Boer,et al.  ST2 and Galectin-3: Ready for Prime Time? , 2016, EJIFCC.

[13]  E. A. Medvedeva,et al.  Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis. , 2016, Minerva cardioangiologica.

[14]  Sergio Lavandero,et al.  Mitochondrial dynamics, mitophagy and cardiovascular disease , 2016, The Journal of physiology.

[15]  Wei Zhang,et al.  Prohibitin overexpression improves myocardial function in diabetic cardiomyopathy , 2015, Oncotarget.

[16]  P. Rossignol,et al.  Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity , 2015, Hypertension.

[17]  F. Zannad,et al.  Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension , 2015, Hypertension.

[18]  E. Nice,et al.  New insights into redox regulation of stem cell self-renewal and differentiation. , 2015, Biochimica et biophysica acta.

[19]  G. Rutteman,et al.  Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis , 2015, PloS one.

[20]  R. D. de Boer,et al.  The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained when Treated with Mineralocorticoid Receptor Antagonists , 2015, PloS one.

[21]  R. Wachter,et al.  Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial , 2015, European journal of heart failure.

[22]  S. Baek,et al.  Short-term use of telmisartan attenuates oxidation and improves Prdx2 expression more than antioxidant β-blockers in the cardiovascular systems of spontaneously hypertensive rats , 2014, Hypertension Research.

[23]  A. Ortiz,et al.  Galectin‐3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis , 2014, Journal of the American Heart Association.

[24]  A. Briones,et al.  Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity , 2014, Journal of hypertension.

[25]  G. Lopaschuk,et al.  Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. , 2013, Biochimica et biophysica acta.

[26]  Bertram Pitt,et al.  Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis , 2013, Circulation. Heart failure.

[27]  R. D. de Boer,et al.  Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[28]  P. van der Harst,et al.  Peroxiredoxin 4, A Novel Circulating Biomarker for Oxidative Stress and the Risk of Incident Cardiovascular Disease and All-Cause Mortality , 2012, Journal of the American Heart Association.

[29]  A. Gow,et al.  Role of reactive nitrogen species generated via inducible nitric oxide synthase in vesicant-induced lung injury, inflammation and altered lung functioning. , 2012, Toxicology and applied pharmacology.

[30]  Seok-Jun Kim,et al.  Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression , 2012, Experimental & Molecular Medicine.

[31]  J. Keaney,et al.  Reactive oxygen species in cardiovascular disease. , 2011, Free radical biology & medicine.

[32]  Hans L Hillege,et al.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.

[33]  Y. Sasaguri,et al.  Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. , 2010, Antioxidants & redox signaling.

[34]  Dirk J. van Veldhuisen,et al.  Galectin-3 in Cardiac Remodeling and Heart Failure , 2010, Current heart failure reports.

[35]  G. Fan,et al.  Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis , 2009, Basic Research in Cardiology.

[36]  P. Karplus,et al.  Typical 2‐Cys peroxiredoxins – structures, mechanisms and functions , 2009, The FEBS journal.

[37]  Xue Leng,et al.  Prohibitin protects against oxidative stress-induced cell injury in cultured neonatal cardiomyocyte , 2009, Cell Stress and Chaperones.

[38]  H. Tsutsui,et al.  Mitochondrial oxidative stress and dysfunction in myocardial remodelling. , 2008, Cardiovascular research.

[39]  M. Krieger,et al.  Peroxiredoxin1 Prevents Excessive Endothelial Activation and Early Atherosclerosis , 2008, Circulation research.

[40]  O. Suzuki,et al.  Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma. , 2008, Oncology reports.

[41]  R. Touyz.  Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? , 2004, Hypertension.

[42]  E. Chi,et al.  Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. , 1995, The American journal of pathology.

[43]  F. Zannad,et al.  The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. , 2015, JACC. Heart failure.